The weekly federal-spending brief. One email a Sunday. Free. No tracking.
The BuildoutBeta
Awards/COOPERATIVE AGREEMENT (B)

$40,877,324

Department of Health and Human Services·National Institutes of Health

to UNIVERSITY OF WISCONSIN SYSTEM

biotechactive
WORK BEGAN2021-04-12·LATEST ACTION·SOURCEUSASPENDING·SOURCE IDASST_NON_UM1AI160040_075
Award description

CHILDHOOD ASTHMA IN URBAN SETTINGS CLINICAL RESEARCH NETWORK - LEADERSHIP CENTER - PROJECT SUMMARY/ABSTRACT THE OVERALL GOALS OF OUR CHILDHOOD ASTHMA IN URBAN SETTINGS (CAUSE)-LEADERSHIP CENTER PROPOSAL ARE TO PROVIDE ADMINISTRATIVE LEADERSHIP AND SUPPORT TO DEVELOP AND CONDUCT COLLABORATIVE RESEARCH TO ADDRESS HIGH PRIORITY UNMET NEEDS FOR CHILDHOOD ASTHMA IN URBAN COMMUNITIES, INCLUDING: A) DEVELOPING STRATEGIES TO PREVENT ASTHMA, B) IMPROVING TREATMENT AND INHIBITING PROGRESSION, C) REDUCING SEVERE EXACERBATIONS, AND D) DEFINING ENDOTYPES OF RESPIRATORY HEALTH AND DISEASE. FOUR HYPOTHESES ARE PROPOSED TO ACCOMPLISH THESE GOALS. FIRST, SUPPLEMENTATION WITH IMMUNE MODULATING BACTERIA IN INFANCY WILL PREVENT THE EARLY LIFE PERTURBATIONS IN THE GUT MICROBIOME THAT HAVE BEEN ASSOCIATED WITH RISK FOR THE DEVELOPMENT OF ALLERGIC SENSITIZATION AND ASTHMA, AND WILL PROMOTE AIRWAY MUCOSAL IMMUNE DEVELOPMENT. SECOND, GIVEN THE IMPORTANCE OF COCKROACH (CR) ALLERGY AND EXPOSURE TO ASTHMA MORBIDITY IN URBAN CHILDREN, CR IMMUNOTHERAPY WILL IMPROVE ASTHMA CONTROL AND REDUCE DISEASE PROGRESSION. THIRD, WE PROPOSE THAT TRANSCRIPTIONAL ANALYSIS OF AIRWAY CELLS WILL DEFINE T2-LOW MECHANISMS THAT CONTRIBUTE TO BOTH NON-ATOPIC AND ATOPIC ASTHMA AND PROVIDE NEW INSIGHTS INTO TREATMENT. FINALLY, MULTI-OMICS EVALUATION OF AIRWAY CELLS AND SECRETIONS OBTAINED DURING SEVERE EXACERBATIONS LEADING TO ED VISITS AND HOSPITALIZATIONS WILL REVEAL NOVEL MECHANISTIC PATHWAYS TO INFORM IMPROVED TREATMENT AND PREVENTION. WE PROPOSE FIVE PROTOCOLS TO TEST THESE HYPOTHESES: 1. URBAN ENVIRONMENT AND CHILDHOOD ASTHMA STUDY (URECA) 2. EFFECTS OF A MICROBIAL SUPPLEMENT (STMC-103H) ON MICROBIAL COLONIZATION AND IMMUNE DEVELOPMENT 3. COCKROACH (CR) IMMUNOTHERAPY (IT) IN URBAN CHILDREN WITH MODERATE-SEVERE ASTHMA PROTECTED BY OMALIZUMAB 4. PATHOGENESIS AND MECHANISMS OF T2-LOW (NON-ATOPIC) ASTHMA 5. SEVERE ASTHMA EXACERBATIONS IN THE EMERGENCY DEPARTMENT (ED) AND HOSPITAL: IDENTIFYING TARGETS FOR PREVENTION AND TREATMENT IT IS OUR EXPECTATION THAT OUR PROPOSED CAUSE RESEARCH PROGRAM WILL PROVIDE CRITICAL INFORMATION NEEDED TO RECOGNIZE ASTHMA PHENOTYPES AND ENDOTYPES IN URBAN CHILDREN, IMPROVE TREATMENT OF ASTHMA AND ESTABLISH DIRECTION FOR PREVENTION. COLLECTIVELY, THESE STUDIES WILL CONTINUE THE RIGOROUS PROGRAMMATIC APPROACH OF THE NIAID ASTHMA NETWORKS TOWARDS ACHIEVING THE LONG-TERM GOALS OF DISEASE MODIFICATION AND PREVENTION OF DISEASE IN HIGH-RISK CHILDREN OF LOW-INCOME FAMILIES LIVING IN URBAN COMMUNITIES.

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high
In plain English

Funds a leadership center and clinical research network studying asthma prevention, mechanisms, and treatment in urban children.

Sub-sectors
nih-research-networkpediatric-asthmaimmunology-research
Why this matters

Childhood asthma disproportionately affects urban communities. This research seeks novel prevention and immune-modulating treatments addressing a major health disparity.

Supply-chain signal

May accelerate development of microbiota therapeutics, immunotherapy platforms, and precision-medicine diagnostics for asthma endotyping.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-06-13. Cost: $0.013108.

Period of performance
Start
2021-04-12
End
2028-03-31
Status
activein 627 days
Sources

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.

$40.9M Department of Health and Human Services — The Buildout — The Buildout